X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1300) 1300
Book Review (114) 114
Publication (45) 45
Newsletter (9) 9
Newspaper Article (7) 7
Conference Proceeding (2) 2
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1215) 1215
humans (1041) 1041
lomustine - administration & dosage (939) 939
male (799) 799
female (753) 753
antineoplastic combined chemotherapy protocols - therapeutic use (644) 644
middle aged (595) 595
adult (564) 564
vincristine - administration & dosage (484) 484
aged (421) 421
oncology (397) 397
procarbazine - administration & dosage (332) 332
chemotherapy (323) 323
cyclophosphamide - administration & dosage (307) 307
brain neoplasms - drug therapy (267) 267
combined modality therapy (267) 267
adolescent (240) 240
lomustine - therapeutic use (237) 237
doxorubicin - administration & dosage (233) 233
lomustine (229) 229
animals (217) 217
drug therapy, combination (210) 210
antineoplastic combined chemotherapy protocols - adverse effects (204) 204
lung neoplasms - drug therapy (190) 190
treatment outcome (190) 190
methotrexate - administration & dosage (178) 178
prognosis (176) 176
lomustine - adverse effects (167) 167
abridged index medicus (162) 162
radiotherapy (151) 151
antineoplastic agents - administration & dosage (149) 149
cancer (149) 149
prednisone - administration & dosage (147) 147
drug administration schedule (144) 144
antineoplastic combined chemotherapy protocols - administration & dosage (143) 143
dacarbazine - administration & dosage (141) 141
etoposide - administration & dosage (136) 136
cisplatin - administration & dosage (132) 132
hodgkin disease - drug therapy (132) 132
clinical trials as topic (131) 131
time factors (131) 131
bleomycin - administration & dosage (129) 129
child (120) 120
carcinoma, small cell - drug therapy (111) 111
follow-up studies (111) 111
vinblastine - administration & dosage (111) 111
brain neoplasms - radiotherapy (110) 110
survival analysis (110) 110
clinical neurology (109) 109
retrospective studies (108) 108
survival rate (107) 107
neoplasm staging (104) 104
glioma - drug therapy (102) 102
survival (100) 100
brain neoplasms - pathology (95) 95
child, preschool (95) 95
disease-free survival (94) 94
mice (94) 94
antineoplastic agents - therapeutic use (91) 91
temozolomide (91) 91
ccnu (90) 90
glioblastoma - drug therapy (89) 89
dose-response relationship, drug (86) 86
therapy (85) 85
neoplasm recurrence, local - drug therapy (84) 84
vincristine (84) 84
remission induction (82) 82
prospective studies (81) 81
dogs (80) 80
veterinary sciences (80) 80
glioblastoma (78) 78
lung neoplasms - mortality (76) 76
melanoma - drug therapy (75) 75
chemotherapy, adjuvant (74) 74
brain neoplasms - mortality (73) 73
fluorouracil - administration & dosage (71) 71
gliomas (71) 71
procarbazine (70) 70
nitrosourea compounds - administration & dosage (69) 69
brain neoplasms - therapy (68) 68
medicine & public health (68) 68
radiotherapy dosage (65) 65
radiation-therapy (64) 64
tumors (64) 64
antineoplastic agents, alkylating - administration & dosage (63) 63
carmustine - administration & dosage (63) 63
vincristine - therapeutic use (62) 62
care and treatment (61) 61
dacarbazine - analogs & derivatives (61) 61
nitrosourea compounds - therapeutic use (61) 61
random allocation (61) 61
antineoplastic agents, alkylating - therapeutic use (60) 60
astrocytoma - drug therapy (60) 60
lomustine - pharmacology (59) 59
mechlorethamine - administration & dosage (58) 58
antineoplastic agents - adverse effects (57) 57
neoplasm metastasis (57) 57
lung neoplasms - radiotherapy (55) 55
cyclophosphamide - therapeutic use (54) 54
cytarabine - administration & dosage (53) 53
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1160) 1160
French (38) 38
Russian (38) 38
German (28) 28
Polish (19) 19
Japanese (10) 10
Chinese (8) 8
Spanish (8) 8
Italian (5) 5
Croatian (1) 1
Czech (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 04/2016, Volume 34, Issue 11, pp. 1175 - 1181
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2005, Volume 23, Issue 36, pp. 9198 - 9207
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2009, Volume 27, Issue 35, pp. 5874 - 5880
Purpose The standard of care for anaplastic gliomas is surgery followed by radiotherapy. The NOA-04 phase III trial compared efficacy and safety of... 
MALIGNANT GLIOMA | SURVIVAL | ONCOLOGY | GLIOBLASTOMA-MULTIFORME | EUROPEAN ORGANIZATION | MGMT GENE | OLIGODENDROGLIAL TUMORS | RADIOTHERAPY | CHEMOTHERAPY | BRAIN-TUMORS | 1P/19Q LOSS | Procarbazine - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Lomustine - adverse effects | Middle Aged | Brain Neoplasms - pathology | DNA Repair Enzymes - genetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents, Alkylating - administration & dosage | Glioma - radiotherapy | Glioma - genetics | Young Adult | DNA Methylation | Time Factors | Radiotherapy, Adjuvant - adverse effects | Glioma - pathology | Treatment Failure | Tumor Suppressor Proteins - genetics | Dacarbazine - analogs & derivatives | Vincristine - administration & dosage | Adult | Female | Brain Neoplasms - mortality | Chemotherapy, Adjuvant | Brain Neoplasms - radiotherapy | Promoter Regions, Genetic | Dacarbazine - administration & dosage | Glioma - mortality | Drug Administration Schedule | Risk Assessment | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Neoplasms - genetics | Isocitrate Dehydrogenase - genetics | Brain Neoplasms - drug therapy | Disease Progression | Disease-Free Survival | DNA Modification Methylases - genetics | Procarbazine - adverse effects | Vincristine - adverse effects | Aged | Mutation | Antineoplastic Agents, Alkylating - adverse effects | Lomustine - administration & dosage | Glioma - drug therapy | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2011, Volume 29, Issue 32, pp. 4227 - 4233
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2010, Volume 28, Issue 30, pp. 4601 - 4608
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2016, Volume 374, Issue 14, pp. 1344 - 1355
Journal Article
Lancet Oncology, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 943 - 953
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 03/2012, Volume 53, Issue 3, pp. 406 - 410
Abstract Polymorphisms of the Glutathione-S Transferase (GST) family may influence the prognosis in lymphoma patients. We aimed to validate the impact of GSTT1... 
GSTT1 | polymorphism | GSTM1 | prognosis | Hodgkin's lymphoma | Prognosis | Polymorphism | SUSCEPTIBILITY | RISK | ACUTE MYELOID-LEUKEMIA | CANCER | CHEMOTHERAPY | GENOTYPES | THERAPY | ONCOLOGY | DISEASE | HEMATOLOGY | ASSOCIATION | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Humans | Middle Aged | Biotransformation - genetics | Male | Carboplatin - pharmacokinetics | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Carboplatin - adverse effects | Anemia - genetics | Glutathione Transferase - physiology | Gene Deletion | Hodgkin Disease - mortality | Vincristine - administration & dosage | Neoplasm Proteins - genetics | Glutathione S-Transferase pi - genetics | Dacarbazine - administration & dosage | Genetic Predisposition to Disease | Prednisone - adverse effects | Anemia - chemically induced | Carboplatin - administration & dosage | Etoposide - administration & dosage | Genotype | Bleomycin - administration & dosage | Doxorubicin - pharmacokinetics | Polymorphism, Genetic | Lomustine - pharmacokinetics | Procarbazine - adverse effects | Vincristine - adverse effects | Cyclophosphamide - pharmacokinetics | Lomustine - administration & dosage | Epirubicin - adverse effects | Etoposide - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hodgkin Disease - genetics | Lomustine - adverse effects | Neoplasm Proteins - physiology | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bleomycin - pharmacokinetics | Epirubicin - administration & dosage | Glutathione S-Transferase pi - physiology | Hodgkin Disease - enzymology | Vinblastine - pharmacokinetics | Glutathione Transferase - genetics | Vinblastine - adverse effects | Vindesine - adverse effects | Hodgkin Disease - drug therapy | Adult | Dacarbazine - pharmacokinetics | Female | Vindesine - pharmacokinetics | Vincristine - pharmacokinetics | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Treatment Outcome | Bleomycin - adverse effects | Procarbazine - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Prednisone - pharmacokinetics | Vindesine - administration & dosage | Epirubicin - pharmacokinetics | Polymorphism, Single Nucleotide | Doxorubicin - adverse effects | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2013, Volume 31, Issue 3, pp. 344 - 350
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 20, pp. 1954 - 1963
The addition of bevacizumab to lomustine in patients with recurrent glioblastoma failed to increase overall survival but was associated with a small increase... 
MEDICINE, GENERAL & INTERNAL | METHYLATION | PROGNOSTIC-FACTORS | PLUS IRINOTECAN | SINGLE-AGENT BEVACIZUMAB | RESPONSE ASSESSMENT | CLINICAL-TRIALS | PHASE-2 | QUALITY-OF-LIFE | RADIOTHERAPY | TEMOZOLOMIDE | Bevacizumab - administration & dosage | Bevacizumab - adverse effects | Humans | Lomustine - adverse effects | Middle Aged | Kaplan-Meier Estimate | Male | Antineoplastic Agents, Alkylating - administration & dosage | Brain Neoplasms - drug therapy | Chemoradiotherapy | Glioblastoma - radiotherapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged, 80 and over | Adult | Female | Aged | Brain Neoplasms - mortality | Antineoplastic Agents, Alkylating - adverse effects | Brain Neoplasms - radiotherapy | Glioblastoma - drug therapy | Glioblastoma - mortality | Lomustine - administration & dosage | Patient outcomes | Lomustine | Outcome and process assessment (Health Care) | Dosage and administration | Research | Drug therapy | Glioblastoma multiforme | Methods | Medical research | Nuclear magnetic resonance--NMR | Brain cancer | Methylguanine | Glioblastoma | Clinical trials | Oncology | Cognition | Cancer therapies | Survival | Quality of life | Bevacizumab | O6-methylguanine-DNA methyltransferase | Studies | Brain research | DNA methylation | DNA methyltransferase | Methylation | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2017, Volume 23, Issue 19, pp. 5745 - 5756
Purpose: Anti-VEGF therapies remain controversial in the treatment of recurrent glioblastoma (GBM). In the current study, we demonstrate that recurrent GBM... 
VASCULAR NORMALIZATION | ANTIANGIOGENIC THERAPY | ADC HISTOGRAM ANALYSIS | ONCOLOGY | SINGLE-AGENT BEVACIZUMAB | TUMOR ANGIOGENESIS | KINASE INHIBITOR | MESENCHYMAL TRANSITION | BRAIN | ENDOTHELIAL GROWTH-FACTOR | ADJUVANT TEMOZOLOMIDE | Recombinant Fusion Proteins - adverse effects | Anilides - adverse effects | Bevacizumab - adverse effects | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Vascular Endothelial Growth Factor A - genetics | Neoplasm Recurrence, Local - pathology | Angiogenesis Inhibitors - administration & dosage | Glioblastoma - diagnostic imaging | Pyridines - adverse effects | Glioblastoma - genetics | Neoplasm Recurrence, Local - diagnostic imaging | Female | Quinazolines - administration & dosage | Angiogenesis Inhibitors - adverse effects | Recombinant Fusion Proteins - administration & dosage | Pyridines - administration & dosage | Bevacizumab - administration & dosage | Receptors, Vascular Endothelial Growth Factor - administration & dosage | Disease-Free Survival | Anilides - administration & dosage | Glioblastoma - pathology | Quinazolines - adverse effects | Neoplasm Recurrence, Local - genetics | Biomarkers, Tumor - genetics | Diffusion Magnetic Resonance Imaging - methods | Glioblastoma - drug therapy | Lomustine - administration & dosage | Neuroimaging | Medical research | Brain | Independent variables | Glioblastoma | Clinical trials | Patients | Survival | Bevacizumab | Magnetic resonance imaging | Experimental design | Medical prognosis | Biomarkers | Bioindicators | Pretreatment | Diffusion coefficient | Diffusion | Vascular endothelial growth factor | Cancer | Index Medicus | recurrent glioblastoma | bevacizumab | Diffusion MRI | cediranib | T1 subtraction | ADC Histogram Analysis | cabozantinib
Journal Article